March 15, 2018 — Women with normal blood pressure during pregnancy and who breastfed their babies for at least six ...

March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiology ...

After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to prevent heart issues while undergoing chemotherapy showed no difference in declines in heart function compared with those taking a placebo. Patients who took carvedilol, however, were significantly less likely to have an elevated marker in the blood that signals injury to the heart, according to a study being presented at the American College of Cardiology’s (ACC) 67th Annual Scientific Session, March 10-12 in Orlando, Fla.

March 13, 2018 – Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein ...

March 13, 2018 – HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement ...

At the American College of Cardiology’s (ACC) 67th Annual Scientific Session and Expo, March 10-12 in Orlando, Fla., Siemens Healthineers launched its new portable cardiovascular ultrasound solution, the Acuson Bonsai.

Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (Nordic Aortic Valve Intervention Trial) at the American College of Cardiology (ACC) 67th Annual Scientific Sessions, March 10-12, 2018, in Orlando Fla. Both studies examined patients with the CoreValve transcatheter aortic valve replacement (TAVR) system at five years post-implant. Results from the studies demonstrated that patients implanted with the CoreValve TAVR system showed strong hemodynamic performance and improved quality of life out to five years.